2022 Highlights

Montefiore Einstein Cardiology

As challenging as 2022 was, Montefiore Einstein Cardiology made impressive strides in research, medical innovation and care. In addition to the many lifesaving procedures we performed, we broadened our footprint by establishing new outpatient and specialty clinics and contributing important scientific studies.


2022 by the numbers

See why 2021 was a remarkable year for us
Explore the numbers




instances of cardiac arrhythmia management


percutaneous valve replacement procedures


noninvasive cardiac imaging studies

Innovations and achievements

Pioneering the future of treatment and care

A multidisciplinary approach to the management of complex cardiometabolic disorders

Dr. Leandro Slipczuk (Cardiac Imaging and Lipid Metabolism), in collaboration with Dr. Molly Fisher (Nephrology), Dr. Sasa Vukelic (Heart Failure and Transplant) and David Carruthers (Endocrinology), leads a program that provides treatment for hundreds of patients with complex disorders of lipid metabolism, uncontrolled diabetes or kidney disease, and who have or are at risk for cardiovascular disease.

Among national leaders in heart transplantation and mechanical circulatory support

We are the one and only destination in New York for bloodless heart transplantation and one of the most active programs attending patients in cardiogenic shock. Our heart transplant survival rates rival the best in the nation.

Novel technologies and approaches aid percutaneous management of valvular and other structural heart diseases

Our department utilizes the most advanced, novel technologies and approaches available to manage complex patients and guide structural interventions. In 2022 our team performed the first in-human completely percutaneous chordal replacement for degenerative mitral valve insufficiency. Our high success rates, excellent outcomes have allow us to increase our volume of procedures by almost 30% over the previous year, becoming one of the largest program in the country.

One of the busiest STEMI programs in the US

Together with the routine use of intracoronary imaging and the latest technologies to approach complex intracoronary lesions, such as intravascular lithotripsy, our management of one of the country’s busiest ST-elevation myocardial infarction (STEMI) programs allows our patients to undergo complete myocardial revascularization with excellent outcomes and noticeable improvement in their quality of life.

A faculty dedicated to research and education

In 2022, we transmitted more than 100 live grand round lectures. Our faculty participated in over 50 national and international meetings and published more than 200 original articles in peer-reviewed journals. Our conferences were transmitted and watched around the world by thousands of healthcare professionals.

Clinical Trials

Advancing care through clinical trials

We participated in over 30 clinical trials in 2022, spanning from novel drugs through advanced devices for the treatment of heart failure, valvular heart disease and arrhythmias. Our investigators performed several first-in-human procedures that sought to offer better treatment options for patients with heart disease.

The Early Feasibility Study of the Transcatheter Tricuspid Valve Replacement System Transfemoral System

Clinical Trial to Evaluate Cardiovascular Outcomes in Patients Treated with the Tricuspid Valve Repair System Pivotal

Edwards PASCAL TrAnScatheter Valve RePair System Pivotal Clinical Trial (CLASP IID/IIF): A Prospective, Multicenter, Randomized, Controlled Pivotal Trial to Evaluate the Safety and Effectiveness of Transcatheter Mitral Valve Repair With the Edwards PASCAL

Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy Using a Novel Device

ACURATE IDE: Transcatheter Replacement of Stenotic Aortic Valve Through Implantation of ACURATE in Subjects InDicatEd for TAVR

AGENT Investigational Device Exemption (IDE)

PROTECT IV Randomized Controlled Trial

Recent investments in our state-of-the-art facilities

We expanded our footprint, opening Montefiore Einstein Advanced Care - Westchester and new outpatient clinics at White Plains Hospital, Wakefield Campus and Montefiore Heart Failure Center at Nyack Hospital. We are also finalizing plans for a comprehensive heart failure initiative, which will include specialty clinics for amyloid, sarcoid, hypertrophic cardiomyopathy and pulmonary hypertension, cardiac intensive care consultations at Nyack Hospital and a new catheterization laboratory. This initiative marks a major step toward solidifying Montefiore’s footprint and heart failure expertise in New York’s Hudson Valley region.

Patient referrals

At Montefiore Einstein Cardiology, we know that providing patients with the best possible care includes teamwork and trust. We work closely with our valued referring physicians to ensure open communication and reliable expertise.